IKENA ONCOLOGY INC (IKNA) Stock Overview
USA - NASDAQ:IKNA - US45175G1085 - Common Stock
IKNA Key Statistics, Chart & Performance
The current stock price of IKNA is 1.43 USD. In the past month the price increased by 6.72%. In the past year, price decreased by -15.88%.
IKNA Latest News, Press Relases and Analysis
IKNA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 51.11 | 781.26B | ||
| JNJ | JOHNSON & JOHNSON | 18.34 | 458.55B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.76 | 258.24B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.73 | 252.36B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 13.65 | 235.32B | ||
| MRK | MERCK & CO. INC. | 11.36 | 218.53B | ||
| PFE | PFIZER INC | 7.3 | 140.77B | ||
| SNY | SANOFI-ADR | 11.74 | 125.85B | ||
| GSK | GSK PLC-SPON ADR | 9.65 | 86.97B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.51 | 89.21B | ||
| ZTS | ZOETIS INC | 23.46 | 64.68B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 50.04 | 44.25B |
Related stock screener links
About IKNA
Company Profile
Ikena Oncology, Inc. is a clinical stage biotechnology company, which engages in the development of patient directed and biomarker driven therapies for cancer patients. The company is headquartered in Boston, Massachusetts and currently employs 10 full-time employees. The company went IPO on 2021-03-26. The firm is focused on developing differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance. Its lead program in the RAS pathway, IK-595, is a molecular glue designed to trap MEK and RAF in an inactive complex, more completely inhibiting RAS signals than existing inhibitors. IK-595’s ability to complex the RAFs, including CRAF prevents a signaling bypass mechanism that cancer cells employ to drive therapeutic resistance to other drugs in this class. IK-595 is being developed as an oral therapy and evaluated in a Phase I clinical trial in RAS and RAF mutant cancers.
Company Info
IKENA ONCOLOGY INC
50 Northern Ave.
Boston MASSACHUSETTS 02210 US
CEO: Mark Manfredi
Employees: 18
Phone: 18573438292
IKENA ONCOLOGY INC / IKNA FAQ
What does IKENA ONCOLOGY INC do?
Ikena Oncology, Inc. is a clinical stage biotechnology company, which engages in the development of patient directed and biomarker driven therapies for cancer patients. The company is headquartered in Boston, Massachusetts and currently employs 10 full-time employees. The company went IPO on 2021-03-26. The firm is focused on developing differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance. Its lead program in the RAS pathway, IK-595, is a molecular glue designed to trap MEK and RAF in an inactive complex, more completely inhibiting RAS signals than existing inhibitors. IK-595’s ability to complex the RAFs, including CRAF prevents a signaling bypass mechanism that cancer cells employ to drive therapeutic resistance to other drugs in this class. IK-595 is being developed as an oral therapy and evaluated in a Phase I clinical trial in RAS and RAF mutant cancers.
What is the stock price of IKENA ONCOLOGY INC today?
The current stock price of IKNA is 1.43 USD. The price increased by 4.38% in the last trading session.
What is the dividend status of IKENA ONCOLOGY INC?
IKNA does not pay a dividend.
What is the ChartMill rating of IKENA ONCOLOGY INC stock?
IKNA has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the number of employees for IKENA ONCOLOGY INC?
IKENA ONCOLOGY INC (IKNA) currently has 18 employees.
What is the market capitalization of IKNA stock?
IKENA ONCOLOGY INC (IKNA) has a market capitalization of 15.99M USD. This makes IKNA a Nano Cap stock.
IKNA Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to IKNA. When comparing the yearly performance of all stocks, IKNA turns out to be only a medium performer in the overall market: it outperformed 47.83% of all stocks.
IKNA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IKNA. While IKNA has a great health rating, there are worries on its profitability.
IKNA Financial Highlights
Over the last trailing twelve months IKNA reported a non-GAAP Earnings per Share(EPS) of -3.28. The EPS decreased by -121.62% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -34.79% | ||
| ROE | -39.1% | ||
| Debt/Equity | 0 |